Genentech drug Gazyva (obinutuzumab) was approved

, , ,

On Nov. 13, 2013, Genentech announced that it’s drug Gazyva (obinutuzumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of people with previously untreated CLL.

Gazyva is a monoclonal antibody designed to attach CD20, a protein found only on B-cells. It attacks targeted cells both directly and together with the body’s immune system.

Gazyva is the fifth cancer medicine from Genentech approved by the FDA in the past three years. Gayzva is the first medicine approved with the FDA’s Breakthrough Therapy Designation

Tags:


Source: Genentech
Credit:

LifeScienceHistory.com offers three advertising package options. Each package lnclude at least two digital images for multiple page placements and maximum exposure! Rates range from just $300 to $500 per month.